Targeting the interaction between Il-17RB and MLK4 inhibits IL-17RB Y447 phosphorylation for cancer treatment
Targeting the interaction between Il-17RB and MLK4 inhibits IL-17RB Y447 phosphorylation for cancer treatment
Docket Number
28A-1090507
Abstract
The present invention relates generally to cancer therapy, in particular breast cancer and pancreatic cancer. The invention is more specifically linked to disruptions specific for blocking interaction of the interleukin - 17B receptor (IL-17RB) and mixed lineage kinase 4 (MLK4). In particular, the invention relates to potent peptide sequence including amino acids 403-416 of IL-17RB for inhibiting oncogenic IL-17B/IL-17RB signaling.
Technological Advantages
- Elucidating the oncogenic signaling of IL-17B/IL-17RB is mediated by IL-17RB Y447 phosphorylation through the interaction of IL-17RB and MLK4
- IL-17RB Y447 phosphorylation is tumor-specific and significantly correlates with the poor prognosis of pancreatic cancer
- Identifying the amino acid 403-416 of IL-17RB can effectively block the interaction between IL-17RB and MLK4
- This technique can be used specifically to inhibit IL-17RB Y447 phosphorylation, block the oncogenic signaling to treat cancer, and can reduce side effects on other normal cells
Applications of Technology
- Targeting the interaction between IL-17RB and MLK4 for cancer treatment
- Amino acid 403-416 of IL-17RB was performed to Interrupt the interaction between IL-17RB and MLK4
- pY447 IL-17RB antibody for detecting oncogenic activation
Inventor
Wen-Hwa Lee, Chun-Mei Hu, Heng-Hsiung Wu
Contact person
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Targeting the interaction between Il-17RB and MLK4 inhibits IL-17RB Y447 phosphorylation for cancer treatment